TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
Triple-negative breast cancer (TNBC) represents a subgroup of breast cancers (BC) associated with the most aggressive clinical behavior. No targeted therapy is currently available for the treatment of patients with TNBC. In order to discover potential therapeutic targets, we searched for protein kin...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/dcb4815980244faa8e17e979409ecdb7 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:dcb4815980244faa8e17e979409ecdb7 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:dcb4815980244faa8e17e979409ecdb72021-11-18T07:45:11ZTTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.1932-620310.1371/journal.pone.0063712https://doaj.org/article/dcb4815980244faa8e17e979409ecdb72013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23700430/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Triple-negative breast cancer (TNBC) represents a subgroup of breast cancers (BC) associated with the most aggressive clinical behavior. No targeted therapy is currently available for the treatment of patients with TNBC. In order to discover potential therapeutic targets, we searched for protein kinases that are overexpressed in human TNBC biopsies and whose silencing in TNBC cell lines causes cell death. A cohort including human BC biopsies obtained at Institut Curie as well as normal tissues has been analyzed at a gene-expression level. The data revealed that the human protein kinase monopolar spindle 1 (hMPS1), also known as TTK and involved in mitotic checkpoint, is specifically overexpressed in TNBC, compared to the other BC subgroups and healthy tissues. We confirmed by immunohistochemistry and reverse phase protein array that TNBC expressed higher levels of TTK protein compared to the other BC subgroups. We then determined the biological effects of TTK depletion by RNA interference, through analyses of tumorigenic capacity and cell viability in different human TNBC cell lines. We found that RNAi-mediated depletion of TTK in various TNBC cell lines severely compromised their viability and their ability to form colonies in an anchorage-independent manner. Moreover, we observed that TTK silencing led to an increase in H2AX phosphorylation, activation of caspases 3/7, sub-G1 cell population accumulation and high annexin V staining, as well as to a decrease in G1 phase cell population and an increased aneuploidy. Altogether, these data indicate that TTK depletion in TNBC cells induces apoptosis. These results point out TTK as a protein kinase overexpressed in TNBC that may represent an attractive therapeutic target specifically for this poor prognosis associated subgroup of breast cancer.Virginie MaireCéline BaldeyronMarion RichardsonBruno TessonAnne Vincent-SalomonEléonore GravierBérengère Marty-ProuvostLeanne De KoningGuillem RigaillAurélie DumontDavid GentienEmmanuel BarillotSergio Roman-RomanStéphane DepilFrancisco CruzaleguiAlain PierréGordon C TuckerThierry DuboisPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 5, p e63712 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Virginie Maire Céline Baldeyron Marion Richardson Bruno Tesson Anne Vincent-Salomon Eléonore Gravier Bérengère Marty-Prouvost Leanne De Koning Guillem Rigaill Aurélie Dumont David Gentien Emmanuel Barillot Sergio Roman-Roman Stéphane Depil Francisco Cruzalegui Alain Pierré Gordon C Tucker Thierry Dubois TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. |
| description |
Triple-negative breast cancer (TNBC) represents a subgroup of breast cancers (BC) associated with the most aggressive clinical behavior. No targeted therapy is currently available for the treatment of patients with TNBC. In order to discover potential therapeutic targets, we searched for protein kinases that are overexpressed in human TNBC biopsies and whose silencing in TNBC cell lines causes cell death. A cohort including human BC biopsies obtained at Institut Curie as well as normal tissues has been analyzed at a gene-expression level. The data revealed that the human protein kinase monopolar spindle 1 (hMPS1), also known as TTK and involved in mitotic checkpoint, is specifically overexpressed in TNBC, compared to the other BC subgroups and healthy tissues. We confirmed by immunohistochemistry and reverse phase protein array that TNBC expressed higher levels of TTK protein compared to the other BC subgroups. We then determined the biological effects of TTK depletion by RNA interference, through analyses of tumorigenic capacity and cell viability in different human TNBC cell lines. We found that RNAi-mediated depletion of TTK in various TNBC cell lines severely compromised their viability and their ability to form colonies in an anchorage-independent manner. Moreover, we observed that TTK silencing led to an increase in H2AX phosphorylation, activation of caspases 3/7, sub-G1 cell population accumulation and high annexin V staining, as well as to a decrease in G1 phase cell population and an increased aneuploidy. Altogether, these data indicate that TTK depletion in TNBC cells induces apoptosis. These results point out TTK as a protein kinase overexpressed in TNBC that may represent an attractive therapeutic target specifically for this poor prognosis associated subgroup of breast cancer. |
| format |
article |
| author |
Virginie Maire Céline Baldeyron Marion Richardson Bruno Tesson Anne Vincent-Salomon Eléonore Gravier Bérengère Marty-Prouvost Leanne De Koning Guillem Rigaill Aurélie Dumont David Gentien Emmanuel Barillot Sergio Roman-Roman Stéphane Depil Francisco Cruzalegui Alain Pierré Gordon C Tucker Thierry Dubois |
| author_facet |
Virginie Maire Céline Baldeyron Marion Richardson Bruno Tesson Anne Vincent-Salomon Eléonore Gravier Bérengère Marty-Prouvost Leanne De Koning Guillem Rigaill Aurélie Dumont David Gentien Emmanuel Barillot Sergio Roman-Roman Stéphane Depil Francisco Cruzalegui Alain Pierré Gordon C Tucker Thierry Dubois |
| author_sort |
Virginie Maire |
| title |
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. |
| title_short |
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. |
| title_full |
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. |
| title_fullStr |
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. |
| title_full_unstemmed |
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. |
| title_sort |
ttk/hmps1 is an attractive therapeutic target for triple-negative breast cancer. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/dcb4815980244faa8e17e979409ecdb7 |
| work_keys_str_mv |
AT virginiemaire ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT celinebaldeyron ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT marionrichardson ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT brunotesson ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT annevincentsalomon ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT eleonoregravier ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT berengeremartyprouvost ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT leannedekoning ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT guillemrigaill ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT aureliedumont ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT davidgentien ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT emmanuelbarillot ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT sergioromanroman ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT stephanedepil ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT franciscocruzalegui ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT alainpierre ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT gordonctucker ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer AT thierrydubois ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer |
| _version_ |
1718423068112584704 |